Clinical-grade cell manufacturing at organ scale
Producing the 10^10-10^11 differentiated, genomically stable human cells of many types that one engineered organ requires, to clinical standard and at acceptable cost.
State of the art
ARPA-H PRINT (up to 176.8 million dollars over five years, awards January 2026) funds cell generation and large-scale manufacturing as two of its three technical areas, explicitly because current batch sizes fall short of one organ.
- Genomic instability and drift accumulate over the expansion needed for 10^11 cells
- Each organ needs many cell types differentiated on a synchronized schedule, not one lineage
- Cost per cell at current media and reagent prices makes a printed organ unaffordable
Who’s working on it
- ARPA-H PRINT ↗Program
Program worth up to $176.8M over five years, with awards from September 2025 through 2026, that funds cell generation and large-scale cell manufacturing explicitly because current batch sizes fall short of one organ
- Cellares ↗Startup
Raised a $257M Series D in January 2026 ($612M total) for automated Smart Factories; its Cell Shuttle holds FDA Advanced Manufacturing Technology designation and delivered its first GMP clinical doses in April 2026
- Lonza ↗Company
The largest contract manufacturer of cell and gene therapies, and the organisation whose unit costs and batch sizes define what clinical-grade means today
- Vertex Pharmaceuticals ↗Company
Manufactures stem-cell-derived islet cells (zimislecel) at clinical scale, the closest existing example of making a large differentiated-cell dose to pharmaceutical standard
- Peter ZandstraResearcherMichael Smith Laboratories, University of British Columbia
Leading authority on bioprocess engineering for pluripotent and blood cell production, including the control theory for keeping differentiation consistent at bioreactor scale
- Wake Forest Institute for Regenerative MedicineAcademic lab
ARPA-H PRINT awardee (September 2025) producing clinical-grade vascularised renal tissue blocks, which forces the cell-supply problem into the open
What to invest in
| Kind | Investment | Scale |
|---|---|---|
| infrastructure | Pilot GMP facilities with closed-system bioreactors sized for organ-scale batches and in-line genomic QC | $$$ $100M – $1B |
| engineering | Low-cost chemically defined media and recombinant growth factors to cut per-cell cost by an order of magnitude | $$ $10M – $100M |
Depends on
A root node: no prerequisites modeled.